Market

Market Opportunity

Over $500m growing WW market due to new indications and new territories

  • U.S.
    – Very few competitors due to Doxil’s complexity
    – Strategic agreement with teir 1 pharma for U.S. comercialization
  • EU
    – Single branded product sold (Caelyx) with no Generic entry

China
– ~$100m market, growing at over 40%  annualy
– Price level similar to U.S. / EU

LC101 Addressing Large Unmet Medical Need

Doxorubicin HCL Liposome injection indications

Ovarian Cancer(1) :

  • 7th most common cancer and 8th most common cause of death from cancer in women worldwide
  • Representing 3.4% (~295K) of cancer cases and 4.4% (~185K) of cancer deaths in 2018
  • Predicted 55% increase in incidence and 67% increase in death by 2035 worldwide

Multiple Myeloma Cancer(2) :

  • Predicted ~32K new cases and ~13K deaths in 2019 in the U.S.


Metastatic Breast Cancer(2,3):

  • Predicted ~270K new cases and 42K deaths in 2019 in the U.S.

(1)  Bhatla, N. and Jones, A., 2018, THE WORLD OVARIAN CANCER COALITION ATLAS GLOBALTRENDS IN INCIDENCE, MORTALITY  & SURVIVAL April 2018

(2)  https://cancerstatisticscenter.cancer.org

(3)  Indicated in EU